Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody”In the company’s words, NCT05271604 on ClinicalTrials.gov
- Tested for
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck, NSCLC, Melanoma
- Main trialPhase 2
- “This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.”In the company’s words, NCT05271604 on ClinicalTrials.gov
- Other names
- BA3071
Other drugs for Head and Neck Cancer
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- APG-157Aveta Biomics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 22 Sep 2025 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | |
| Phase 1/2Unknown | 19 Mar 2025 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026